Multiple Myeloma Clinical Trials
Multiple myeloma clinical trials provide patients with exciting opportunities to be among the first to receive and benefit from promising new treatments before those options are widely available in other settings. In doing so, participants also help to accelerate the development of next-generation treatments that will benefit all current and future cancer patients.
The Safety of Clinical Trials
The purpose of a clinical trial is to assess the effectiveness of a new treatment in comparison to that of existing treatments. Prior to being used a clinical trial, a new treatment is tested extensively to confirm its safety. Many people assume that placebos are used in cancer clinical trials, but that is not the case. Instead, a participant can expect to receive either a brand-new treatment or the current “best standard” treatment that is currently available.
Multiple Myeloma Clinical Trial Program at Moffitt
At Moffitt Cancer Center, we perform extensive research and have an active multiple myeloma clinical trials program. Our scientists and clinicians are currently evaluating:
- Drug therapies to control myeloma or alleviate symptoms
- Stem cell transplants used in combination with high-dose chemotherapy
- Bisphosphonates for treating bone complications that often accompany multiple myeloma
- Radiation therapy to destroy the cancer cells or inhibit their growth
- Surgical techniques designed to repair fractures, manage pain and improve function and mobility
As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt continues to lead the way in cancer research. Our multiple myeloma clinical trials are transforming the treatment landscape by eliminating obstacles and speeding up every step of the drug research and development process. These important research studies are the most reliable scientific method for determining whether a new treatment works better than the current standard of care.
To learn more about the multiple myeloma clinical trials currently underway at Moffitt, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. We can help you determine whether you qualify for one of our trials, and we do not require referrals.
-
Clinical Trials
CLINICAL TRIAL 20113
Phase 1/2 FIH Study of Regn5458 (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: REGN5458 (); Tocilizumab ()
CLINICAL TRIAL 21219
Predicting Progression of Developing Myeloma in a High-Risk Screened Population
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 21752
Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
Condition: Multiple
Intervention:
CLINICAL TRIAL 22596
Clonal Hematopoiesis, Clonal Cytopenia, Myeloid Neoplasms Study Group
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 23203
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRCSD Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: BMS-986453 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23322
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 23335
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 23422
Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Condition: Malignant Hematology
Intervention: Not Applicable ()
CLINICAL TRIAL 23563
A Phase 1b trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: Iberdomide (); Teclistamab ()
CLINICAL TRIAL 23586
A Phase 1b/2 Study of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants with Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: AZD0120 (); GC012F (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23570
Feasibility of Dietary Interventions for Optimizing CAR-T Cell Function in Cancer Patients and Adults without Cancer
Condition: Multiple
Intervention:
CLINICAL TRIAL 23630
A Phase 1/2 Platform Study with Etentamig in Subjects with Multiple Myeloma
Condition: Malignant Hematology
Intervention: ABBV-2001 (); CC-5013 (Lenalidomide); Daratumumab (Darzalex); Dexamethasone (); Etentamig (); Iberdomide (); Lenalidomide (Revlimid); Mezigdomide (); abbv-383 (Etentamig); carfilzomib (Kyprolis)
CLINICAL TRIAL 23741
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 23778
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
Condition: Multiple Myeloma
Intervention: JNJ-68284528 (ciltacabtagene autoleucel); ciltacabtagene autoleucel ()
CLINICAL TRIAL 23819
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 23937
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Condition: Malignant Hematology
Intervention: JNJ-79635322 (); Teclistamab ()
CLINICAL TRIAL 24145
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-BCMA CAR-T Cells in Patients with Relapsed and Refractory Multiple Myeloma
Condition: Immunotherapy
Intervention: KLN-1010 ()
CLINICAL TRIAL 24157
Artificial Intelligence for Widespread Awareness, Research and Education (AWARE): Establishing the Framework for Tailored AI Tools for Multiple Myeloma
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 24175
Expanded Access Program for Mezigdomide (in combination with Carfilzomib/dex or Bortezomib/dex) For Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Condition: Malignant Hematology
Intervention:
CLINICAL TRIAL 24176
A Phase 1, First-in-Human, Open Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: ABBV-438 ()
CLINICAL TRIAL 24241
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
Condition: Malignant Hematology
Intervention: